Jan 30, 2019

Congress shows its hand on drug prices

Sen. Chuck Grassley during a Judiciary Committee hearing last year. (Photo: Chip Somodevilla/Getty Images)

A key Senate panel seemed to hone in yesterday on some bipartisan ideas to cut federal spending on prescription drugs.

The big picture: Members of the Senate Finance Committee were mostly interested in proposals that would cut payments to insurance companies and doctors, though some also raised questions about pharmaceutical companies.

Details: Republicans and Democrats were both open to restructuring Medicare Part D, including payments to insurers.

  • “There’s reporting that patterns of overbidding exist that may indicate a potential gaming of the system," Finance Chairman Chuck Grassley told Axios, alluding to a recent Wall Street Journal story that said insurers have pocketed an extra $9.1 billion because of the way they estimate their costs.

In Medicare Part B, senators discussed changing the way the government reimburses doctors for the drugs they buy — "getting away from a percentage, which creates an incentive to go with the most expensive possible prescription and instead going with something closer to a flat fee," Sen. Pat Toomey said.

  • Doctors and hospitals have fought such changes before, and are fighting a similar proposal from the Trump administration. Critics say the current arrangement gives doctors an incentive to use the most expensive drugs, because they collect a percentage of the cost.

There was also support for changing the way pharmacy benefit managers handle their rebates, which the pharmaceutical industry may support and Trump is also considering.

"I thought there was a big swath of ground for bipartisanship," Sen. Ron Wyden said.

Grassley also hinted at more dramatic price cuts for drugs in an interview, but offered few details.

  • With more transparency throughout the system, "the companies have to justify their price increases and have uniform pricing," he said. "Whether I buy a drug or you buy a drug, there ought to be one price for a drug and everybody ought to pay the same thing."
  • A source familiar with Grassley's thinking said he was not advocating for price controls.
  • Other committee Republicans also questioned the gap between drug companies' profits and their research spending, but did not endorse any proposals to limit those profits.

Go deeper

Scoop: New White House personnel chief tells Cabinet liaisons to target Never Trumpers

McEntee, shown with White House counselor Kellyanne Conway and White House senior adviser Stephen Miller, walks on the South Lawn of the White House Jan. 9. Photo: Drew Angerer/Getty Images

Johnny McEntee called in White House liaisons from cabinet agencies for an introductory meeting Thursday, in which he asked them to identify political appointees across the U.S. government who are believed to be anti-Trump, three sources familiar with the meeting tell Axios.

Behind the scenes: McEntee, a 29-year-old former body man to Trump who was fired in 2018 by then-Chief of Staff John Kelly but recently rehired — and promoted to head the presidential personnel office — foreshadowed sweeping personnel changes across government.

How art can help us understand AI

Photo: Ina Fried/Axios

Activists and journalists have been telling us for years that we are handing too much of our human autonomy over to machines and algorithms. Now artists have a showcase in the heart of Silicon Valley to highlight concerns around facial recognition, algorithmic bias and automation.

Why it matters: Art and technology have been partners for millennia, as Steve Jobs liked to remind us. But the opening of "Uncanny Valley: Being Human in the Age of AI" tomorrow at the de Young Museum in San Francisco's Golden Gate Park puts art in the role of technology's questioner, challenger — and sometimes prosecutor.

The Deontay Wilder-Tyson Fury fight is the rematch of the century

Illustration: Eniola Odetunde/Axios

The weekend's biggest sporting event is Wilder-Fury II, which despite its name is not an action movie sequel starring Jean-Claude Van Damme but, rather, a boxing match starring arguably the two best heavyweights in the world.

The backdrop: In their first meeting in December 2018, Deontay Wilder and Tyson Fury put on a memorable show at Staples Center, with Fury surviving a brutal right hand in the 12th round to earn a split-decision draw.

Go deeperArrow2 hours ago - Sports